Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease

Vascular Medicine

Volumn 9, Issue 3, 2004, Pages 189-192

  Karagiannis, Asterios ^a,b   Balaska, Katerina ^a   Tziomalos, Konstantinos ^a   Gerasimidis, Thomas ^a   Karamanos, Dimitrios ^a   Papayeoryiou, Athanasios ^a   Zamboulis, Chrysanthos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Angiotensin converting enzyme gene polymorphism; Peripheral arterial occlusive disease

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ALLELES; ARTERIAL OCCLUSIVE DISEASES; BRACHIAL ARTERY; CROSS-SECTIONAL STUDIES; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREECE; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PERIPHERAL VASCULAR DISEASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 12344318583     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm5540a     Document Type: Article

References (44)

1. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (suppl 11): S13-S18.
2. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993; 11: 1155-59.
3. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163: 284-91.
4. Alhenc-Gelas F, Richard J, Courdon D, Warnet JM, Corvol P. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med 1991; 117: 33-39.
5. Soubrier F, Alhenc-Gelas F, Hubert C et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Sci U S A 1988; 85: 9386-90.
6. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-46.
7. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-44.
8. Ross RR. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
9. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DPC 1) (dipeptidyl carboxypeptidase 1). Nucleic Acid Res 1992; 20(6): 1433.
10. Shanmugan V, Sell K, Saha B. Mistyping ACE heterozygotes. PCR Methods Appl 1993; 3: 120-21.
11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
12. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial: The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
13. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28.
14. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-87.
15. Haberbosch W, Bohle RM, Franke FE et al. The expression of angiotensin-I converting enzymme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 1997; 130: 203-13.
16. Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi A. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol 1996; 271: H1065-H71.
17. Hoshida S, Nishida M, Yamashita N et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 1997; 130: 53-59.
18. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16: 44-50.
19. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62: 749-56.
20. Ferrario CM, Deitch JS, Dean RH, Strawn WB. Hypertension and atherosclerosis a mechanistic understanding of disease progression. Cardiovasc Risk Factors 1996; 6: 299-310.
21. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
22. Potter DD, Sobey CG, Thompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98: 800-807.
23. Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Effect of angiotensin II and enalapril on transfer of low-density lipoprotein into aortic intima in rabbits. Circ Res 1994; 75: 63-69.
24. Cardona-Sanclemente LE, Born GV. Increase by adrenaline or angiotensin II of the accumulation of low-density lipoprotein and fibrinogen by aortic walls in unrestrained conscious rats. Br J Pharmacol 1996; 117: 1089-94.
25. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31.
26. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1992; 20: 473-77.
27. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: S65-S72.
28. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993; 91: 1453-58.
29. Charpiot P, Rolland PH, Friggi A et al. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 1993; 13: 1125-38.
30. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin-converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994; 108: 61-72.
31. Strawn WB, Gallagher PE, Tallant EA, Ganten D, Ferrario CM. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. J Cardiovasc Pharmacol 1999; 33: 341-51.
32. Keidar S, Attias J, Smith J, Breslow J, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 1997; 236: 622-25.
33. Strawn WB, Chappel MC, Ferrario CM. Losartan reduces LDL susceptibility to oxidation and circulating markers of inflammation in hyperlipoproteinemic monkeys. Hypertension 1999; 34: 328 (abstract)
34. Fukuhara M, Geary RL, Diz DI et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35 [part 2]: 353-59.
35. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psychiatry 1998; 64: 227-30.
36. Zee RYL, Ridker PM, Stampfer MJ, Hennekens CH, Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation 1999; 99: 340-43.
37. Missouris CG, Barley J, Jeffery S, Carter ND, Singer DR, MacGregor GA. Genetic risk for renal artery stenosis: association with deletion polymorphism in angiotensin I-converting enzyme gene. Kidney Int 1996; 49: 534-37.
38. Losito A, Selvi A, Jeffery S, Afzal AR, Parente B, Cao PG. Angiotensin-converting enzyme gene I/D polymorphism and carotid artery disease in renovascular hypertension. Am J Hypertens 2000; 13 128-33.
39. Dessi-Fulgheri P, Catalini R, Sarzani R et al. Angiotensin-converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population. J Hypertens 1995; 13 1593-96.
40. Watanabe Y, Ishigami T, Kawano Y et al. Angiotensin-converting enzyme gene I/D polymorphism and carotid plaques in Japanese. Hypertension 1997; 30 [part 2]: 569-73.
41. O'Donnell CJ, Lindpaintner K, Larson MG et al. Evidence for associaton and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998; 97: 1766-72.
42. Schunkert H, Hense HW, Holmer SR et al. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-38.
43. Taute BM, Handschug K, Taute R, Seifert H, Glaser C, Podhaisky H. Angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral arterial occlusive disease. Vasa 1998; 27: 149-53.
44. Renner W, Pabst E, Paulweber B et al. The angiotensin-converting-enzyme insertion/deletion polymorphism is not a risk factor for peripheral arterial disease. Atherosclerosis 2002; 165: 175-78.